Drug Trial Radar · NCT05718167
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
Last checked: Nov 19, 2026Latest source record: Feb 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
570
Planned (sponsor's estimate)
Start
Feb 2023
Primary completion
Oct 2024
Study completion Oct 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450 injection combined with Anlotinib Hydrochloride Capsules versus Tislelizumab injection combined with Paclitaxel Injection and Carboplatin Injection followed by Tislelizumab injection in locally advanced (stage ⅢB/ⅢC) and metastatic or recurrent (Stage IV) squamous NSCLC subjects.The primary endpoint is PFS assessed by IRC.
Conditions
- Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions
TQB2450Drug
TQB2450 is a humanized monoclonal antibody targeting the programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, making T cells recover their activity, thereby enhancing the immune response.
Anlotinib hydrochloride capsuleDrug
Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor, which can target angiogenesis related kinases, such as VEGFR 1/2/3, FGFR 1/2/3 and other tumor cell proliferation related kinases like Platelet-derived growth factor receptor (PDGFR) α/β、 C-kit, RET.
Tislelizumab injectionDrug
Tislelizumab injection can bind to human programmed cell death 1 (PD-1), a cell membrane protein that is mainly expressed on activated T cells and inhibits T cell activation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Base line up to 2 years. The curative effect was evaluated every 6 weeks (42 days) in the first 54 weeks of treatment period; After 54 weeks, the efficacy was evaluated every 9 weeks (63 days).
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences Cancer Hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
TianJin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.